Immunotherapy on Breast Cancer
A Brief and Concise Overview
DOI:
https://doi.org/10.58445/rars.1648Keywords:
Breast Cancer, tumors, cancerAbstract
Breast cancer remains the second most widespread and fatal malignancy in females.
Scientists can inhibit unregulated cell growth and destruction using newly developed
immunotherapy methods like protein kinase B (AKT) Inhibitors. This therapy is designed for
prevention rather than fighting tumors head-on with radiotherapy and chemotherapy. This offers
less harmful symptoms while still providing effective care. Furthermore, immunology is still in
development since many cancers remain resistant to it. Previously, breast cancer has been
considered non-immunogenic, but after recent and ongoing clinical trials, data shows discovered
vulnerabilities in the molecular level of breast cancer. These studies will lead to developments in
life-saving immunology treatments. We aimed to review immunology and how scientists have
advanced immunotherapy in breast cancer and discuss ongoing clinical trials
References
McCarthy, E. F. (2006). The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopaedic Journal, 26, 154–158.
Ayoub, N. M., Al-Shami, K. M., & Yaghan, R. J. (2019). Immunotherapy for HER2-positive breast cancer: Recent advances and combination therapeutic approaches. Breast Cancer: Targets and Therapy, 11, 53–69. https://doi.org/10.2147/BCTT.S175360
Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer–immune set point. Nature, 541(7637), 321–330. https://doi.org/10.1038/nature21349
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361–1365. https://doi.org/10.1126/science.aar6711
Weiner, L. M., Surana, R., & Wang, S. (2010). Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 10(5), 317–327. https://doi.org/10.1038/nri2744
Andrews, L. P., Yano, H., Vignali, D. A. A., & Workman, C. J. (2019). New insights into the mechanisms of immune checkpoint inhibitor therapy. Nature Reviews Immunology, 19(12), 703–714. https://doi.org/10.1038/s41577-019-0200-z
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., ... & Krummel, M. F. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 24(5), 541–550. https://doi.org/10.1038/s41591-018-0014-x
McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell, 168(4), 613–628. https://doi.org/10.1016/j.cell.2017.01.018
Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell, 161(2), 205–214. https://doi.org/10.1016/j.cell.2015.03.030
Ye, F., Dewanjee, S., Li, Y., et al. (2023). Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular Cancer, 22, 105. https://doi.org/10.1186/s12943-023-01805-y
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., et al. (2021). Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduction and Targeted Therapy, 6(1), 425. https://doi.org/10.1038/s41392-021-00828-5
Hudis, C., Swanton, C., Janjigian, Y. Y., Lee, R., Sutherland, S., Lehman, R., et al. (2013). A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research, 15(6), R110. https://doi.org/10.1186/bcr3577
Australian New Zealand Clinical Trials Registry. (n.d.). Phase II study of ipilimumab and nivolumab with neoadjuvant paclitaxel for early-stage TNBC. Trial ID: ACTRN12617000651381. Retrieved from https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373073
Downloads
Posted
Categories
License
Copyright (c) 2024 Gavin Andrada
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.